
while there is evidence of path-deviant change at the institutional level (i.e. regulatory
change) in both countries, it has not led to hybridization or path-deviant change at the
organization level.
While it is true that some of the large Germany companies, such as Hoechst, Bayer
and BASF, have restructured their organizations, this was less an expression of organiz-
ational hybridization, as Lane claims (2000), than of ‘greater specialization in national
industrial profiles’ (Vitols, 2001: 360; Sorge, 2003). Unable to enter new growth fields
(i.e. biotechnology),
21
which require more radical innovation, these three companies dis-
posed of their pharmaceuticals subsidiaries. Initially, all three companies relocated their
innovative activities in pharmaceuticals to the USA, either through the establishment of
new research facilities there or through the acquisition of existing firms (particularly in
the biotechnology area). More recently, however, it seems that German companies are
simply disappearing from the pharmaceutical industry. Hoechst disappeared as a German
pharma company by merging with the French Rhône-Poulenc, with the new company’s
headquarters (Aventis) in France. BASF has sold all of its pharmaceutical operations to a
US company, and Bayer is also argued to have increased its focus on core competencies,
and the current preference is towards maintaining chemicals activities and selling off
pharmaceuticals (Vitols, 2001). It seems, then, that far more than hybridization, what is
happening in this industry points to further specialization.
Further specialization does not occur at the level of societal institutions, however, as
was also predicted by the second assumption. Rather, as indicated,we have discussed some
evidence of path-deviant change at that level. In fact, it seems that path-deviant reforms
in Germany and Japan, which allow for Anglo-Saxon-style management practices, con-
tribute to intensified specialization at the industrial level. For example, the tax reform in
Germany, which was expected to lead to the unwinding of cross-holdings, rather than
doing so, in general stimulated the divestment of non-core activities. Similarly, in Japan,
in order to attract young employees, some companies bypassed the institutionalized
seniority-based wage system and implemented Anglo-Saxon-style remuneration pack-
ages that are performance-based. However, rather than diluting the entire system, these
measures, at the same time, enabled these companies to preserve lifetime employment,
which is one of the cornerstones of the Japanese production model. This model has a com-
parative advantage in the so-called medium-tech sectors characterized by incremental
innovation and large firm-specific human capital investments.
In general, it would not be wrong to argue that there is more evidence of path
dependency and resilience than of hybridization or path-deviant change at the organiz-
ation and management level. This finding can perhaps best be explained by the dynamics
of bargaining processes within the insider or stakeholder model, which strive to obtain an
equilibrium situation between diverging interests and acquired rights, including those of
labour. While it is true that regulatory reform shows tendencies that could be perceived as
path-deviant in both Germany and Japan, its effects point to the wish to preserve and revi-
talize the current model. These findings lead to the conclusion that the choice of a
particular level of analysis, to a large extent, determines the type of evidence one obtains
and, thus, the argument that one is able to defend. When the research focus is on societal
542 COMPARATIVE INTERNATIONAL MANAGEMENT
21
See Casper (2000) for an extended explanation of incremental adaptation in a largely path-dependent way in
German biotechnology companies.
MG9353 ch12.qxp 10/3/05 8:49 am Page 542